ACM Global Central Laboratory Establishes Mumbai-based Subsidiary to Strengthen Lab Services in India
ACM Global Central Lab has advanced its hybrid central lab model in Mumbai with a state-of-the art operational facility dedicated to manage clinical trials testing in India and provide study support throughout Asia Pacific. Working in conjunction with the largest diagnostic lab in the region, ACM Global oversees the full complement of study support to keep clinical trials on schedule and on budget, including kit building, shipping logistics, projectmanagement, data management, and site support.
“We have been able to build a local team that thoroughly understands the nuances of the market, plus the systems and process at ACM Global to maintain our high global standard for global clinical trial testing,” said Nandan Rao, director, India and general manager, Asia Pacific at ACM Global Central Lab.
ACM Global first established an operational footprint in India seven years ago, and established its hybrid lab model three years ago to support increased activity in the Asia Pacific region. This has enabled ACM Global to take advantage of an established, regional central lab while benefitting from its own advanced data management systems for the centralization and harmonization of test data. With a local staff, data is integrated immediately with the centralized database, and shipping and logistics are navigated at the local level, which means tighter specimen controls and lower total costs to the sponsor.
All studies conducted by the CAP-certified lab are assured precise analytical data managed from a central location with one harmonized database
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
